

Impact of Clinical Guideline Updates on the LDL-C Screening component of the HEDIS Comprehensive Diabetes Care Measure (NQF 0063)

In response to the release of the guideline below, NCQA retired the LDL-C Screening and LCL-C Control components of the HEDIS Comprehensive Diabetes Care Measure in the 2015 version of HEDIS.¹ NCQA has not added new components to replace them.

The American College of Cardiology/ American Heart Association (ACC/ AHA) Task Force on Practice Guidelines released updated guidance for the treatment of cholesterol for the primary or secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in November 2013.² The Task Force asserted that no studies have focused on treatment or titration to a specific LDL-C goal in adults with clinical ASCVD but rather have confirmed the efficacy of a single fixed-dose statin therapy to lower LDL-C levels in patients with clinical ASCVD. Therefore, the Task Force recommended that the focus of treatment should be shifted from LDL-C or non-HDL-C treatment targets for LDL-C to the intensity of statin therapy based on patient risk factors.

¹ <http://www.ncqa.org/Newsroom/NewsArchive/2014NewsArchive/NewsReleaseJuly12014.aspx>

² <http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a>